Novavax (NASDAQ:NVAX) Price Target Raised to $9.00 at TD Cowen

Novavax (NASDAQ:NVAX) had its target price raised by equities researchers at TD Cowen from $8.00 to $9.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective indicates a potential downside of 4.17% from the company’s current price.

NVAX has been the subject of several other reports. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings raised shares of Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. BTIG Research reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a research report on Tuesday, January 20th. B. Riley Financial reissued a “buy” rating on shares of Novavax in a research report on Thursday, April 9th. Finally, HC Wainwright boosted their price target on shares of Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.13.

Novavax Price Performance

Shares of Novavax stock traded up $1.29 during trading on Wednesday, hitting $9.39. 14,373,480 shares of the stock were exchanged, compared to its average volume of 4,706,678. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 3.90 and a beta of 2.37. The firm’s 50-day moving average price is $9.06 and its 200 day moving average price is $8.19. Novavax has a 12-month low of $5.80 and a 12-month high of $11.97.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.19. The business had revenue of $118.90 million during the quarter, compared to analysts’ expectations of $78.32 million. Novavax had a net margin of 39.19% and a negative return on equity of 673.17%. The company’s revenue for the quarter was down 79.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.93 EPS. As a group, research analysts forecast that Novavax will post -0.06 earnings per share for the current year.

Institutional Investors Weigh In On Novavax

A number of institutional investors and hedge funds have recently made changes to their positions in NVAX. Flagship Harbor Advisors LLC purchased a new stake in shares of Novavax in the fourth quarter valued at about $33,000. Quarry LP purchased a new stake in shares of Novavax in the third quarter valued at about $33,000. Duncker Streett & Co. Inc. raised its holdings in shares of Novavax by 917.3% in the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,825 shares during the last quarter. State of Wyoming purchased a new stake in shares of Novavax in the second quarter valued at about $52,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,617 shares during the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

More Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q1 beats — Novavax reported a GAAP loss of $0.06/share versus consensus ~?$0.25 and delivered revenue that topped estimates, helped by milestone and licensing payments. This upside is the primary near-term catalyst behind the stock strength. Novavax beats first-quarter revenue estimates on vaccine deals strength
• Positive Sentiment: High-margin partnerships — Management highlighted multiple licensing/MTA deals (including a non?exclusive Pfizer Matrix?M license and expanded MTAs with large pharma/oncology partners) that generated milestone cash and improve near?term revenue visibility without direct product sales. Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Pipeline & validation signals — Sanofi’s Phase 4 COMPARE results were cited as reinforcing Nuvaxovid’s differentiated reactogenicity profile; Novavax also flagged a C. difficile candidate prioritized to potentially enter the clinic as early as 2027, supporting longer?term upside. Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
• Neutral Sentiment: Company commentary — Novavax reiterated its 2026 revenue framework and combined R&D + SG&A guidance, and provided slides/transcript for investors; these details will matter for models but are not an immediate binary catalyst. Listen to Conference Call
• Negative Sentiment: Full?year revenue outlook below Street — Novavax’s FY2026 revenue framework is materially below consensus (management’s range is well under prior Street estimates), creating downside risk for analyst forecasts and valuation until guidance is re?rated. Listen to Conference Call
• Negative Sentiment: Sharp year?over?year revenue decline — Q1 revenue is down roughly ~79% YoY, reflecting weak product demand and making Novavax more reliant on licensing/milestone cash versus recurring sales. That makes future quarters lumpy and guidance execution critical. Novavax earnings and presentation

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.